ArticleTranslational oncology2019

DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties.

Maria Goulielmaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.